Table 1.
Variable | Controls (n = 19) | All patients (n = 71) | WHO grade II patients (n = 41) | WHO grade III patients (n = 17) | WHO grade IV patients (n = 13) |
---|---|---|---|---|---|
Age in years (SD) | 43.7 (8.7) | 43.8 (11.2) | 42.5 (9.5) | 42.6 (12.6) | 49.5 (13.4) |
Number of males (females) | 8 (11) | 46 (25) | 23 (18) | 12 (5) | 11 (2) |
Number of patients with KPS 90–100 (KPS 70–80)⁎ | NA | 30 (41) | 21 (20) | 8 (9) | 1 (12) |
Mean motion (SD) | 0.081 (0.039) | 0.089 (0.039) | 0.082 (0.037) | 0.092 (0.029) | 0.110 (0.052) |
Median number of movements > 5 mm (range) | 0 (0–3) | 0 (0–5) | 0 (0–5) | 0 (0–5) | 1 (0–5) |
Number of patients with 0/1/>2 missing regions | NA | 44/18/9 | 30/8/3 | 10/4/3 | 4/6/3 |
Median hub overlap strict/proportional (range)⁎ | NA | 3/2 (0–9/0–6) | 2/2 (0–8/0–6) | 4/3 (0–9/0–6) | 2/2 (0–5/0–5) |
Mean tumor volume in cm3 (SD) | NA | 685 (545) | 542 (488) | 860 (536) | 909 (574) |
Number of patients with A/O/OA/GBM | NA | 26/21/11/13 | 19/13/9/0 | 7/8/2/0 | 0/0/0/13 |
Number of patients with LOH/no LOH/unknown | NA | 14/4/53 | 4/1/36 | 10/3/4 | 0/0/13 |
Number of patients with left (right) tumor lateralization | NA | 40 (31) | 23 (18) | 9 (8) | 8 (5) |
Median OS in months (number of censored patients) | NA | 30 (50) | 48 (33) | 38 (14) | 16 (3) |
Median PFS in months (number of censored patients) | NA | 19.5 (25) | 23 (14) | 51 (10) | 7.5 (1) |
Number of patients with epilepsy (without) | NA | 53 (18) | 31 (10) | 12 (5) | 10 (3) |
Number of patients on DEX/not on DEX/unknown | NA | 6/63/2 | 0/39/2 | 1/16/0 | 5/8/0 |
Indicates p < 0.05 difference between tumor grades. WHO = World Health Organization; SD = standard deviation; KPS = Karnofsky performance status; NA = not applicable; A = astrocytoma; O = oligodendroglioma; OA = oligoastrocytoma; GBM = glioblastoma multiforme; LOH = loss of heterozygosity; OS = overall survival; PFS progression free survival; DEX = dexamethasone.